ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021. It is up by over 770% from its lowest point in 2023, giving it a market cap of almost $6 billion. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins. Future acquisition likely? Copy link to section ImmunityBio shares have been in a str ...